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Abstract
Background: About 500 new smear-positive Multidrug-resistant tuberculosis (MDR-TB) cases are estimated to occur
per year in Uganda. In 2008 in Kampala, MDR-TB prevalence was reported as 1.0% and 12.3% in new and
previously treated TB cases respectively. Line probe assays (LPAs) have been recently approved for use in low
income settings and can be used to screen smear-positive sputum specimens for resistance to rifampicin and
isoniazid in 1-2 days.
Methods: We assessed the performance of a commercial line probe assay (Genotype MTBDRplus) for rapid
detection of rifampicin and isoniazid resistance directly on smear-positive sputum specimens from 118 previously
treated TB patients in a reference laboratory in Kampala, Uganda. Results were compared with MGIT 960 liquid
culture and drug susceptibility testing (DST). LPA testing was also performed in parallel in a University laboratory to
assess the reproducibility of results.
Results: Overall, 95.8% of smear-positive specimens gave interpretable results within 1-2 days using LPA. Sensitivity,
specificity, positive and negative predictive values were 100.0%, 96.1%, 83.3% and 100.0% for detection of
rifampicin resistance; 80.8%, 100.0%, 100.0% and 93.0% for detection of isoniazid resistance; and 92.3%, 96.2%,
80.0% and 98.7% for detection of multidrug-resistance compared with conventional results. Reproducibility of LPA
results was very high with 98.1% concordance of results between the two laboratories.
Conclusions: LPA is an appropriate tool for rapid screening for MDR-TB in Uganda and has the potential to
substantially reduce the turnaround time of DST results. Careful attention must be paid to training, supervision and
adherence to stringent laboratory protocols to ensure high quality results during routine implementation.
Background
Uganda had an estimated incidence of all forms of TB
of 330 per 100, 000 population in 2007, of which 136
per 100 000 were sputum smear positive. 0.5% of new
TB cases and 4.4% of previously treated cases were mul-
tidrug resistant in 1997 [1]. However a recent drug
resistance survey performed in Kampala reported preva-
lence of any drug resistance as 12.7% (63/497) and
31.6% (18/57), and MDR-TB prevalence of 1.0% (5/497)
and 12.3% (7/57) in new and previously treated smear-
positive TB cases respectively [2]. About 500 new
smear-positive MDR-TB cases are estimated to occur
per year in the country [1].
Recently the World Health Organisation (WHO)
recommended the use of molecular line probe assays
(LPAs) for rapid screening of MDR-TB in low and mid-
dle income settings [3]. LPAs use multiplex polymerase
chain reaction (PCR) amplification and reverse hybridi-
zation to identify M. tuberculosis complex and muta-
tions to genes associated with rifampicin and isoniazid
resistance. LPA can be performed directly from acid fast
bacilli (AFB) smear-positive sputum, or from culture
isolates, and provide results in 1-2 days. A recent sys-
tematic review concluded that line probe assays are
highly sensitive and specific for detection of rifampicin
resistance (≥97% and ≥99%) and isoniazid resistance
(≥90% and ≥99%) on culture isolates and smear-positive
sputum. Overall agreement with conventional DST for
detection of MDR-TB was 99% [4].
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are currently detected worldwide. Lack of laboratory
capacity in high TB burden countries, notably in sub-
Saharan Africa, is a barrier to control of drug resistant
TB. Conventional drug susceptibility testing (DST) is a
slow process and can take 2-4 months or longer, during
which time a patient is often treated according to the
standard regimen for drug-susceptible TB. The resultant
delay in proper treatment may adversely affect treatment
outcome and contribute to the transmission of drug-
resistant disease and amplification of drug resistance.
Furthermore, due to financial, infrastructural and
human resource requirements, widespread implementa-
tion of culture-based DST may be challenging in such
settings. Specimen transport and specimen contamina-
tion issues may also present further challenges [5]. Thus
implementation of rapid molecular methods for detect-
ing drug-resistant TB may be a viable alternative to cul-
ture-based DST in Uganda.
In response to the need to scale up access to TB diag-
nostic services, UNITAID has recently funded a project
to introduce new TB diagnostics in selected low income
countries. Project partners include WHO - Global
Laboratory Initiative (GLI), FIND and the Stop TB Part-
nership’s Global Drug Facility (GDF). This project has
recently been expanded to include 27 countries, of
which 12 are in sub-Saharan Africa, including Uganda.
We report on a local validation of rapid molecular
testing using line probe assays for screening MDR-TB in
Uganda, which was carried out as the first step in imple-
mentation of the LPA technology in the country.
Methods
Study setting
Previously treated pulmonary tuberculosis patients were
enrolled at the Tuberculosis Unit at Mulago National
Referral Hospital, Kampala. The line probe assay (LPA)
testing and MGIT culture and DST were carried out at
the Tuberculosis Research Laboratory operated by the
Foundation for Innovative New Diagnostics (FIND)
based at the National Tuberculosis Reference Laboratory
(NTRL) in Kampala, Uganda. Inter-laboratory LPA
testing was performed at the Department of Medical
Microbiology, Makerere University and specimen decon-
tamination and primary culture was carried out at the
NTRL. The study was approved by Makerere University
and Mulago Hospital Ethics committees.
Specimen collection and processing
Smear-positive sputum was collected from patients at
risk of MDR-TB at Mulago Hospital Previously treated
TB suspects attending the Mulago National Referral
Hospital TB Unit were consecutively screened for acid
fast bacilli (AFBs) using Ziehl-Neelsen (ZN) smear
microscopy, as part of a larger study investigating a
number of rapid drug susceptibility test methods. All
consenting smear positive patients were enrolled. Two
or three sputum samples (spot or morning) were col-
lected per patient in 50 ml sterile conical centrifuge
tubes.
All manipulations with potentially infectious clinical
specimens were performed in a Class II safety cabinet in
a BSL 2 or 3 Laboratory. Sputum was processed with
the N-acetyl-L-cysteine-sodium hydroxide (NaOH)
method (NaOH final concentration, 1.5%).
Any processed specimen remaining was stored at 2-8°
C for the duration of the study to allow for re-testing of
specimens giving discrepant results.
Conventional laboratory testing
Sputum specimens submitted for smear, culture and
DST were processed using N-acetyl-cysteine-sodium
hydroxide (NALC-NaOH) decontamination (NaOH final
concentration, 1.5%) [6]. Following centrifugation, the
pellet in each tube was suspended in 2.5 ml of phos-
phate buffer pH 6.8. Processed sediments from the same
patient were pooled and mixed thoroughly. A concen-
trated auramine smear was prepared and examined
under × 400 magnification using a fluorescence micro-
scope and graded according to WHO/IUATLD guide-
lines [7]. Samples were cultured using the BACTEC
MGIT 960 system (Becton Dickinson Microbiology Sys-
tems, Cockeysville, MD, USA) and Lowenstein-Jensen
solid medium. Primary isolates were stored at -80°C. For
MGIT DST, frozen isolates were cultured using MGIT
960 system and confirmed as M. tuberculosis complex
using Capilia TB Neo (TAUNS Corporation, Japan) and
checked for contamination by growth on blood agar
medium for 48 hours at 37°C prior to setting up DST
for isoniazid and rifampicin according to manufacturer’s
instructions (0.1 μg/ml isoniazid and 1 μg/ml
rifampicin).
Any processed specimen remaining after initial cul-
tures was stored at -20°C for the duration of the study
to allow for re-testing of specimens in case of invalid
results.
Line probe assay (LPA)
LPA testing was performed in three separate rooms,
according to WHO recommendations [3]. DNA extrac-
tion was performed in the BSL3 laboratory, master mix
preparation in a second room, and PCR and hybridisa-
tion were performed in a third laboratory. Five hundred
microlitres of processed sediment was used to perform
the Genotype MTBDRplus (Hain Lifescience GmbH)
assay, according to the manufacturer’si n s t r u c t i o n s[ 8 ] .
LPA was performed without knowledge of conventional
DST results. Residual processed specimens were
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allow repeat testing if required. In parallel, LPA testing
was also performed on processed sediments in a blinded
fashion at Makerere University Department of Medicine
molecular biology laboratory.
Repeat testing and discrepant analysis
LPA testing on samples with invalid results were
repeated using the stored residual extracted DNA. To
consider a band valid for study purposes, the band
intensity had to be equal or greater than the AC band
(according to the product insert).
Inter-laboratory comparison
Testing at the University laboratory was completely
independent of testing in the FIND-NTRL laboratory
and was performed without knowledge of conventional
DST results. Results from the University laboratory were
reported and included in the data analysis after comple-
tion of all testing.
Data analysis
The sensitivity, specificity, PPV, NPV and overall accu-
racy of LPA results were compared to the conventional
MGIT DST results for rifampicin, isoniazid, multidrug
resistance and the ability of rifampicin resistance alone
to predict MDR. An analysis of banding patterns asso-
ciated with rifampicin and isoniazid resistance in MDR-
TB and non MDR-TB strains was performed.
Statistical tests were performed using Intercooled
STATA 8.0 software (Statacorp LP, College Station, TX,
USA) and Microsoft Excel 7.0 (Microsoft Corporation).
Results were considered significant at p < 0.05.
Results
Overall, 118 pooled smear-positive sputum specimens
(118 patients) were tested by LPA. Of these, 53 (44.9%)
were 3+ AFB smear-positive, 31 (26.3%) were 2+ smear-
positive, 30 (25.4%) were 1+ smear-positive and 4 (3.4%)
were very low positive (6-8 AFBs).
Conventional DST results were only available for 92
specimens. The remainder was not available due to lack
of growth from the frozen primary isolate (15), isolation
of non-tuberculous mycobacteria (1), contamination (2)
or unavailability of frozen isolate for MGIT DST (8).
Interpretation of LPA results
A total of 113/118 (95.8%) specimens gave interpretable
LPA results overall, including results of repeat testing
which was performed in 23 cases. The causes of repeat
testing included no TUB band for 16 specimens (a sin-
gle batch of 6 specimens also had lack of AC band on
the negative control), rpoB band being very faint or
absent (2), or faint or indistinct bands (5).
The proportionof invalid results (after repeat testing) was
related to smear status, with 1.9% (1/53), 3.2% (1/31), 6.7%
(2/30) and 25.0% (1/4) of results being invalid for 3+, 2+, 1+
and scanty smear-positive sputum specimens respectively.
A summary of LPA results, including results of repeat
testing where performed, is shown in Table 1. Five strains
were initially considered to be sensitive during the initial
interpretation by the technologists, when strictly following
the product insert, which states: “only those bands whose
intensities are about as strong as or stronger than that of
the Amplification control zone are to be considered”.
However, when re-checked by the supervisor, these strains
were considered to be resistant since mutation bands were
present, although they were somewhat weaker than the
amplification control. These strains were also considered
to be resistant by the University laboratory (read indepen-
dently from the research laboratory). All 5 strains were
later confirmed to be drug resistant by MGIT DST.
Performance parameters for LPA were calculated by
comparison with conventional culture and DST results
(Table 2). The sensitivity for detection of rifampicin, iso-
niazid and multidrug resistance was 100.0%, 80.8% and
92.3% respectively. Specificity for detection of rifampi-
cin, isoniazid and multidrug resistance was 96.1%,
100.0% and 96.2% respectively. When rifampicin resis-
tance alone was used as an indicator for MDR-TB, the
agreement remained very high, with 96.7% of results
correctly predicting MDR.
Banding patterns
The patterns of mutations associated with rifampicin
and isoniazid resistance in multidrug resistant and
mono-resistant strains is shown in Table 3.
Table 1 Performance of line probe assay (LPA) in smear-
positive sputum specimens compared with conventional
drug susceptibility testing (MGIT DST)
MGIT DST
INH
R
RIF
R
INH
R
RIF
S
INH
S
RIF
R
INH
S
RIF
S
No
result*
LPA INH
R RIF
R 12 3 0 0 4
INH
R RIF
S 06000
INH
S RIF
R 10212
INH
S RIF
S 0406 3 1 5
Indeterminate 00005
LPA, line probe assay
MGIT DST, Mycobacterial Growth Indicator Tube
RIF
S, rifampicin susceptible; RIF
R, rifampicin resistant
INH
S, isoniazid susceptible; INH
R, isoniazid resistant
* No result was due to lack of growth from the frozen primary isolate (15),
isolation of non-tuberculous mycobacteria (1), contamination (2) or
unavailability of frozen isolate for MGIT DST (8).
Indeterminate results included are those remaining without an interpretable
result after repeat testing.
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positive sputum specimens
Rifampicin Isoniazid Multi-drug resistance Rifampicin as predictor of MDR
No. resistant/No. susceptible strains 15/77 26/66 13/79 13/79
Sensitivity, %
(95% CI)
100.0%
(78.2 - 100.0)*
80.8%
(60.6 - 93.4)
92.3%
(64.0 - 99.8)
100.0%
(75.3-100.0)*
Specificity, %
(95% CI)
96.1%
(89.0 - 99.2)
100.0%
(94.5 - 100.0)*
96.2%
(89.3 - 99.2)
96.2%
(89.3 - 99.2)
Overall accuracy, % (95% CI) 96.7%
(90.8 - 99.3)
94.6
(87.8 - 98.2)
95.7%
(89.2 - 98.8)
96.7%
(90.7 - 99.3)
PPV, %
(95% CI)
83.3%
(58.6 - 96.4)
100.0%
(83.9 - 100.0) *
80.0%
(51.9 - 95.7)
81.3%
(54.3 - 96.0)
NPV, %
(95% CI)
100.0%
(95.1 - 100.0)
93.0%
(84.3 - 97.7)
98.7%
(92.9 - 100.0)
100.0%
(95.3 - 100.0)*
* one-sided, 97.5% confidence interval
Table 3 Pattern of gene mutations detected by Genotype MTBDRplus assay in drug resistant M. tuberculosis strains
Gene Band Gene region or mutation MDR strains*
(n = 13)
RIF monoresistant strains*
(n = 6)
INH monoresistant
strains*
(n = 13)**
rpoB
WT1 506-509
WT2 510-513 1
WT3 513-517 1 2
WT4 516-519 1
WT5 518-522
WT6 521-525
WT7 526-529 1 1
WT8 530-533 1 1
MUT1 D516V
MUT2A H526Y
MUT2B H526D 1
MUT3 S531L 9 1
katG
WT 315 1 1
MUT1 S315T1 9 7
MUT2 S315T2
inhA
WT1 -15/-16 1#
WT2 -8
MUT1 C15T 2 1
MUT2 A16G
MUT3A T8C
MUT3B T8A
* by conventional drug susceptibility testing (MGIT DST)
1 MDR strain had both rpoB WT3 and WT4 mutations, 1 MDR had both rpoB WT4 and WT7 mutations.
# this strain also had katG S315T1 mutation.
1 MDR strain did not have mutation in either katG or inhA.
** 4 INH mono-resistant strains had no mutations detected in inhA or katG.
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Of the 118 smear-positive specimens, 117 were tested by
the University laboratory. Overall, 109 specimens gave
interpretable results, with 20 MDR-TB and 89 non-
MDR-TB results. 8 specimens gave indeterminate
results. There was very high concordance (98.1%)
between results obtained by FIND-NTRL laboratory and
the University laboratory. Two specimens were reported
as MDR-TB by the University laboratory but non MDR
(rifampicin monoresistant) by the FIND-NTRL labora-
tory. One of these specimens was confirmed as MDR-
TB by MGIT DST and the other specimen had no
MGIT DST result available. Table 4 shows the compari-
son of results for the 88 specimens in which both LPA
and MGIT DST results were available.
Discussion
The performance of LPA directly from smear-positive
sputum correlated very highly with culture and DST
performed on MGIT 960. Overall, an acceptable propor-
tion of valid results was obtained. Initial invalid results
were largely due to insufficient DNA in two batches of
tests which may be due to operator error in the extrac-
tion process. Repeat testing gave interpretable results in
most cases. As previously reported, the proportion of
invalid results was correlated with smear status, with
much higher failure rates in very low smear-positive
specimens [9].
As reported widely elsewhere, rifampicin resistance
was highly associated with mutation in the 81 base pair
region of the rpoB gene [10,11]. In this study it was
most commonly associated with mutation in the region
of rpoB 530-533, mostly S531L mutation. This mutation
was more frequently found in MDR strains than in
rifampicin monoresistant strains. This is in common
with findings in a recent South African study [9]. Isonia-
zid resistance was most commonly associated with katG
S315T1 mutation, as is the case in many high TB bur-
den countries, presumably related to ongoing transmis-
sion of these strains [12]. This was equally the case in
MDR and INH monoresistant strains, although the over-
all number of strains was small. The performance of the
LPA in this setting was similar to that reported pre-
viously, with high specificity for detection of rifampicin
and isoniazid, high sensitivity for detection of rifampicin
resistance, and somewhat lower sensitivity for isoniazid
resistance [4]. One MDR strain in this study did not
reveal mutations in the selected katG or inhA loci
which are detected by this test. The strain was not
further investigated as to the mutation(s) associated
with INH resistance in this case. Studies from a number
of countries have reported variability in the association
of isoniazid resistance with mutations in katG or inhA
[13].
Laboratory technologists performing the assay at the
NTRL-FIND Laboratory had no previous experience of
molecular diagnostics, and had undergone 4 days of
LPA training immediately prior to starting the study.
This may explain the fact that invalid results were initi-
ally obtained on some batches, and may be related to
operator error during DNA extraction. However, perfor-
mance overall in the validation study was very good,
and comparable with results in other settings. In addi-
tion, results were highly reproducible with >98% of
results in concordance with results of independent test-
ing performed at the University laboratory.
Although in most cases the interpretation of banding
patterns was very straightforward, in a few specimens
weak mutation bands were present, which if strictly
applying recommendations in the product insert would
be considered as susceptible. However, we found the
presence of weak mutation bands was associated with
drug resistance in all cases in this study. This needs to
be further confirmed in testing of a larger number of
specimens.
The technologists involved in this study considered 4
days training to be sufficient. However as evidenced by
the initial problem with invalid results, as well as diffi-
culty interpreting weak mutation bands and dealing with
contamination, a longer supervised period during early
implementation of the technology is advisable, and the
availability of an experienced molecular biologist in per-
son, or at the very least by regular email contact, is criti-
cal in troubleshooting problems especially during the
initial stages.
Issues to be considered during implementation of LPA
in high TB burden countries include supply of consum-
ables and reagents not provided as part of the kit, such
Table 4 Comparison of line probe assay (LPA) results
from FIND-NTRL and University laboratory (specimens in
which both LPA and MGIT DST results were available)
MGIT DST result LPA results Number of
specimens
RIF
R INH
R (n = 12) Lab 1 and Lab 2 MDR 11
Lab 1 RIF
R INH
S; Lab 2 MDR 1
RIF
S INH
R (n = 13) Lab 1 and Lab 2 RIF
R INH
R 3
Lab 1 and Lab 2 RIF
S INH
R 6
Lab 1 and Lab 2 RIF
S INH
S 4
RIF
R INH
S (n = 2) Lab 1 and Lab 2 RIF
R INH
S 2
RIF
R INH
S (n = 61) Lab 1 and Lab 2 RIF
S INH
S 59
Lab 1 RIF
S INH
R; Lab 2 RIF
S INH
S 2
Total 88
Lab 1, FIND-NTRL laboratory
Lab 2, University laboratory
RIF
S, rifampicin susceptible; RIF
R, rifampicin resistant
INH
S, isoniazid susceptible; INH
R, isoniazid resistant
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Page 5 of 7as pipette tips and molecular grade water. Furthermore,
the necessary infrastructure for performing LPA should
be considered prior to implementation - a minimum of
three separate rooms is recommended to minimise the
risk of contamination. Restricted access to the molecular
laboratories and strict adherence to standard operating
procedures are necessary to reduce the risk of amplicon
contamination. During this study, we experienced a sin-
gle minor contamination episode at the FIND-NTRL
laboratory involving splashing from one well to another
during the hybridization process leading to contamina-
tion of the negative control strip, necessitating repeating
the batch of testing.
The NTRL has established a specimen referral net-
work which is being rolled out in at the regional level to
enable transport of smear-positive specimens from
MDR-TB suspects for DST. Currently DST is performed
using MGIT 960, but this comes with a number of chal-
lenges related to the need for cold storage of specimens
during transport and high level of contamination. Imple-
mentation of LPA is anticipated to lead to a more rapid
turnaround time, and a higher proportion of valid
results, as well as eliminating the need for cold storage
(unless culture is also to be performed on the same spe-
cimens). With expansion of routine LPA testing, it will
be critical to implement quality assurance procedures,
and to provide access to technical support for laboratory
staff, to ensure consistency of results.
LPAs are currently validated only for use directly from
smear-positive specimens, although reasonable perfor-
mance in a small sample of smear-negative specimens
was demonstrated by Barnard and colleagues [9].
Although smear-positive TB cases are the most infec-
tious [14], smear-negative TB in high HIV prevalent set-
tings such as Uganda is responsible for substantial
morbidity and mortality [15]. In Uganda, for example,
sputum smear-positive cases represent only 41% of all
new TB cases per year [1].
Ongoing research into improved DNA extraction
methods may enable LPAs to be performed directly
from smear-negative sputum in future. However the
cost-effectiveness of routine testing of smear-negative
specimens would have to be carefully evaluated since
the majority of specimens will be negative in most
settings.
LPA supplies are available in Uganda at a reduced
price. As part of its role in the development and evalua-
tion process of new diagnostic technologies, FIND has
negotiated with the manufacturing partner to obtain sig-
nificant price reductions for equipment and reagents for
LPA testing for the public health sector in high burden
countries in order to facilitate widespread access to
WHO-approved technologies [16].
Conclusions
LPA is an appropriate tool for rapid screening for MDR-
TB in the Ugandan reference laboratory setting and has
the potential to substantially reduce the turnaround
time of DST results. However, WHO recommendations
on infrastructure, training, quality assurance and other
requirements should be followed to ensure high quality
results. Good communication between laboratory and
clinical personnel is critical to ensure rapid referral of
specimens and receipt of results to enable the full bene-
fit of rapid diagnostics to be realised. Furthermore, roll
out of improved diagnostic technologies should happen
in parallel with plans for increasing MDR-TB manage-
ment capacity, as implementation of a rapid diagnostic
such as LPA can only impact on patient care as part of
a holistic approach to MDR-TB management.
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